Reduced Lp(a) with PCSK9 inhibitors in individuals with high Lp(a) at baseline contributes to CV risk reduction
This video was recorded at the EAS in Maastricht, the Netherlands, on May 29, 2019.
John Chapman is Research Professor at the Sorbonne University, is affiliated with the Endocrinology-Metabolism Division of the Pitié-Salpêtrière University Hospital, and is Director Emeritus of the National Institute for Health and Medical Research (INSERM) in Paris, France.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.